Literature DB >> 23908345

Increased atherosclerotic lesion formation and vascular leukocyte accumulation in renal impairment are mediated by interleukin-17A.

Shuwang Ge1, Barbara Hertel, Ekaterina K Koltsova, Inga Sörensen-Zender, Jan T Kielstein, Klaus Ley, Hermann Haller, Sibylle von Vietinghoff.   

Abstract

RATIONALE: Atherosclerosis is a major cause of death in patients with chronic kidney disease. Chronic inflammation of the arterial wall including invasion, proliferation, and differentiation of leukocytes is important in atherosclerotic lesion development. How atherosclerotic inflammation is altered in renal impairment is incompletely understood.
OBJECTIVE: This study analyzed leukocytes of the atherosclerotic aorta in mice with impaired and normal renal function and studied a mechanism for the alteration in aortic myeloid leukocytes. METHODS AND
RESULTS: Unilateral nephrectomy significantly decreased glomerular filtration rate and increased atherosclerotic lesion size and aortic leukocyte numbers in 2 murine atherosclerosis models, apolipoprotein E (Apoe(-/-)) and low-density lipoprotein (LDL) receptor-deficient (LDLr(-/-)) mice. The number of aortic myeloid cells increased significantly. They took-up less oxidized LDL, whereas CD11c expression, interaction with T cells, and aortic T cell proliferation were significantly enhanced in renal impairment. In human peripheral blood mononuclear cell cultures, chronic kidney disease serum decreased lipid uptake and increased human leukocyte antigen II (HLA II) expression. Supplementation with interleukin-17A similarly increased HLA II and CD11c expression and impaired oxidized LDL uptake. Interleukin-17A expression was increased in atherosclerotic mice with renal impairment. Ablation of interleukin-17A in LDLr(-/-) mice by lethal irradiation and reconstitution with Il17a(-/-) bone marrow abolished the effect of renal impairment on aortic CD11b(+) myeloid cell accumulation, CD11c expression, and cell proliferation. Atherosclerotic lesion size was decreased to levels observed in normal kidney function.
CONCLUSIONS: Kidney function modifies arterial myeloid cell accumulation and phenotype in atherosclerosis. Our results suggest a central role for interleukin-17A in aggravation of vascular inflammation and atherosclerosis in renal impairment.

Entities:  

Keywords:  atherosclerosis; interleukin-17; leukocytes; renal insufficiency; vascular inflammation

Mesh:

Substances:

Year:  2013        PMID: 23908345      PMCID: PMC3848055          DOI: 10.1161/CIRCRESAHA.113.301934

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  60 in total

1.  Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.

Authors:  Eisuke Suganuma; Yiqin Zuo; Nobuhiko Ayabe; Ji Ma; Vladimir R Babaev; Macrae F Linton; Sergio Fazio; Iekuni Ichikawa; Agnes B Fogo; Valentina Kon
Journal:  J Am Soc Nephrol       Date:  2005-12-21       Impact factor: 10.121

Review 2.  Chronic kidney disease and mortality risk: a systematic review.

Authors:  Marcello Tonelli; Natasha Wiebe; Bruce Culleton; Andrew House; Chris Rabbat; Mei Fok; Finlay McAlister; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2006-05-31       Impact factor: 10.121

Review 3.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

Review 4.  Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue.

Authors:  G Wick; M Romen; A Amberger; B Metzler; M Mayr; G Falkensammer; Q Xu
Journal:  FASEB J       Date:  1997-11       Impact factor: 5.191

5.  The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells.

Authors:  Dennis A Hesselink; Michiel G H Betjes; Martijn A Verkade; Petros Athanassopoulos; Carla C Baan; Willem Weimar
Journal:  Nephrol Dial Transplant       Date:  2005-05-10       Impact factor: 5.992

6.  Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice.

Authors:  Ziad A Massy; Ognen Ivanovski; Thao Nguyen-Khoa; Jesus Angulo; Dorota Szumilak; Nadya Mothu; Olivier Phan; Michel Daudon; Bernard Lacour; Tilman B Drüeke; Martin S Muntzel
Journal:  J Am Soc Nephrol       Date:  2004-11-24       Impact factor: 10.121

Review 7.  Dendritic cells in atherosclerosis: current status of the problem and clinical relevance.

Authors:  Yuri V Bobryshev
Journal:  Eur Heart J       Date:  2005-04-26       Impact factor: 29.983

8.  Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice.

Authors:  Susanne Bro; Flemming Moeller; Claus B Andersen; Klaus Olgaard; Lars B Nielsen
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

9.  Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques.

Authors:  M D Rekhter; D Gordon
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

Review 10.  Anti-inflammatory therapy in chronic disease: challenges and opportunities.

Authors:  Ira Tabas; Christopher K Glass
Journal:  Science       Date:  2013-01-11       Impact factor: 47.728

View more
  10 in total

Review 1.  Extracellular vesicles as mediators of vascular inflammation in kidney disease.

Authors:  Alexandra Helmke; Sibylle von Vietinghoff
Journal:  World J Nephrol       Date:  2016-03-06

Review 2.  Cytokine Circuits in Cardiovascular Disease.

Authors:  Jesse W Williams; Li-Hao Huang; Gwendalyn J Randolph
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

3.  Upregulation of OLR1 and IL17A genes and their association with blood glucose and lipid levels in femoropopliteal artery disease.

Authors:  Caner Arslan; Burcu Bayoglu; Cigdem Tel; Mujgan Cengiz; Ahmet Dirican; Kazim Besirli
Journal:  Exp Ther Med       Date:  2017-01-24       Impact factor: 2.447

4.  Myeloid CCR2 Promotes Atherosclerosis after AKI.

Authors:  Anne M Hüsing; Vera C Wulfmeyer; Svenja Gaedcke; Susanne V Fleig; Song Rong; David DeLuca; Hermann Haller; Roland Schmitt; Sibylle von Vietinghoff
Journal:  J Am Soc Nephrol       Date:  2022-05-10       Impact factor: 14.978

5.  T Cell CX3CR1 Mediates Excess Atherosclerotic Inflammation in Renal Impairment.

Authors:  Lei Dong; Johannes Nordlohne; Shuwang Ge; Barbara Hertel; Anette Melk; Song Rong; Hermann Haller; Sibylle von Vietinghoff
Journal:  J Am Soc Nephrol       Date:  2015-10-08       Impact factor: 10.121

6.  A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).

Authors:  Joel M Gelfand; Daniel B Shin; Kristina Callis Duffin; April W Armstrong; Andrew Blauvelt; Stephen K Tyring; Alan Menter; Scott Gottlieb; Benjamin N Lockshin; Eric L Simpson; Farid Kianifard; Rajendra Prasad Sarkar; Elisa Muscianisi; Jennifer Steadman; Mark A Ahlman; Martin P Playford; Aditya A Joshi; Amit K Dey; Thomas J Werner; Abass Alavi; Nehal N Mehta
Journal:  J Invest Dermatol       Date:  2020-02-21       Impact factor: 8.551

7.  Aggravated Atherosclerosis and Vascular Inflammation With Reduced Kidney Function Depend on Interleukin-17 Receptor A and Are Normalized by Inhibition of Interleukin-17A.

Authors:  Johannes Nordlohne; Alexandra Helmke; Shuwang Ge; Song Rong; Rongjun Chen; Ari Waisman; Hermann Haller; Sibylle von Vietinghoff
Journal:  JACC Basic Transl Sci       Date:  2018-01-10

8.  A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia.

Authors:  Young Uk Kim; Patrick Kee; Delia Danila; Ba-Bie Teng
Journal:  Immune Netw       Date:  2019-12-04       Impact factor: 6.303

Review 9.  Cytokines as therapeutic targets for cardio- and cerebrovascular diseases.

Authors:  Luca Liberale; Stefano Ministrini; Federico Carbone; Giovanni G Camici; Fabrizio Montecucco
Journal:  Basic Res Cardiol       Date:  2021-03-26       Impact factor: 17.165

Review 10.  Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.

Authors:  Eunhye Ji; Sahmin Lee
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.